The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Open accessAbstract
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). CONCLUSIONS: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“chemotherapy plus immune checkpoint blockade has been recently approved as the first-line regimen for NSCLC, including patients with KRAS mutations (45, 46).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Importantly, two remarkable phase III trials (KEYNOTE-189 and KEYNOTE-407) demonstrated that addition of pembrolizumab (Keytruda, anti-PD1) could significantly prolong the survival of NSCLC patients (45, 97).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“The promising results from these studies have led to the approval of pembrolizumab in combination with chemotherapy (carboplatin-pemetrexed) for metastatic, non-squamous NSCLC, and the approval of pembrolizumab in combination with chemotherapy (carboplatin and Taxol) for patients with squamous lung carcinoma, excluding those carrying EGFR or ALK mutations.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Toward this end, combinations of ICTs with concurrent and/or sequential chemotherapy are under extensive investigation, with phase III clinical data demonstrating overall survival and/or progression-free survival benefi t in NSCLC ( 63-66 ), small cell lung cancer ( 51,52 ), triple-negative breast cancer ( 67 ), bladder cancer ( 53 ), and head and neck squamous cell carcinoma ( 68 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [64]
In the citing paper
“Later, in two phase 3 clinical studies (KEYNOTE-189 and KEYNOTE-407), pembrolizumab combined with standard chemotherapy led to a better overall survival (OS) and PFS in NSCLC patients, relative to chemotherapy monotherapy [53, 54].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [54]
In the citing paper
“Moreover, ORR, median PFS, and median DOR reported for the two treatment arms were consistent with those reported in the KEYNOTE-189 and KEYNOTE-407 trials of pembrolizumab i.v.þ chemotherapy for the treatment of mNSCLC.22,23”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,006
The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer
Jain, R., Coss, C. C., Whooley, P. D., Phelps, M. A., & Owen, D. H. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00916-9 · Cited by 47
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
Qu, J., Wang, L., Jiang, M., Zhao, D., Wang, Y., Zhang, F., Li, J., & Zhang, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s257188 · Cited by 46
Pavan, A., Bragadin, A. B., Calvetti, L., Ferro, A., Zulato, E., Attili, I., Nardo, G., Maso, A. D., Frega, S., Menin, A. G., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-674 · Cited by 47
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
Xiong, W. G., Zhao, Y., Du, H., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704336 · Cited by 47
Awad, M. M., Bruchec, Y. L., Lu, B. D., Ye, J. Y., Miller, J., Lizotte, P. H., Cavanaugh, M. E., Rode, A. J., Dumitru, C. D., & Spira, A. I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.696512 · Cited by 45
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study
Ravi, V., Subramaniam, A., Zheng, J., Amini, B., Trinh, V. A., Joseph, J., Mennel, R. G., Bishop, A. J., Sturgis, E. M., Goepfert, R. P., et al. (2022) · Cancer · doi:10.1002/cncr.34370 · Cited by 46
Chen, B., Yao, W., Li, X., Lin, G., Chu, Q., Liu, H., Du, Y., Lin, J., Duan, H., Wang, H., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02519-0 · Cited by 43
Self-citationAssessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
Veith, I., Nurmik, M., Mencattini, A., Damei, I., Lansche, C., Brosseau, S., Gropplero, G., Corgnac, S., Filippi, J., Poté, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101549 · Cited by 49
Onesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46
Immune Checkpoint Inhibitors in Lung Cancer and Melanoma
Madden, K. M., & Kasler, M. K. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.011 · Cited by 45
Ye, X., Wei, Z., Yang, X., Huang, G., Li, W., Han, X., Wang, J., Meng, M., Ni, Y., Zou, Z., et al. (2019) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_990_19 · Cited by 45
Benítez, J. C., Recondo, G., Rassy, E., & Mezquita, L. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03250-1 · Cited by 45
Cavazzoni, A., Digiacomo, G., Alfieri, R. R., Monica, S. L., Fumarola, C., Galetti, M., Bonelli, M. A., Cretella, D., Barili, V., Zecca, A., et al. (2020) · Cancers · doi:10.3390/cancers12030666 · Cited by 45
Yan, X., Tian, X., Wu, Z., & Han, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01671 · Cited by 45
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
Li, L., Li, G., Rao, B., Dong, A.-H., Liang, W., Zhu, J., Qin, M.-P., Huang, W., Lu, J., Li, Z.-F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72649-5 · Cited by 46
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
Tfayli, A., Assaad, M. A., Fakhri, G. B., Akel, R., Atwi, H., Ghanem, H., Karak, F. E., Farhat, F. S., rabi, K. A., Sfeir, P. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3456 · Cited by 45
Batra, A., Sheka, D., Kong, S., & Cheung, W. Y. (2020) · BMC Cancer · doi:10.1186/s12885-020-07487-9 · Cited by 44
Nadler, E., Arondekar, B. V., Aguilar, K. M., Zhou, J., Chang, J., Zhang, X., & Pawar, V. S. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03414-4 · Cited by 48
Berti, A., Bortolotti, R., Dipasquale, M., Kinspergher, S., Prokop, L. J., Grandi, G., Inchiostro, S., Paolazzi, G., Caffo, O., & Veccia, A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103351 · Cited by 49
Tumor microenvironment in lung cancer-derived brain metastasis
Liu, W., Powell, C. A., & Wang, Q. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002127 · Cited by 49
Parisi, C., Mahjoubi, L., Gazzah, A., & Barlési, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102572 · Cited by 44
Zhang, Z., Pan, Q., Lu, M., & Zhao, B. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102156 · Cited by 46
Zhao, Y., Chen, G., Li, X., Wu, J., Chang, B., Hu, S., Yang, S., Xu, T. S., Liu, Y., Wang, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101470 · Cited by 46
Self-citationGadgeel, S. M., Rodríguez‐Abreu, D., Halmos, B., Garassino, M. C., Kurata, T., Cheng, Y., Jensen, E. H., Shamoun, M., Rajagopalan, K., & Paz-Ares, L. G. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.04.011 · Cited by 47
Self-citationShen, K., Cui, J., Wei, Y., Chen, X., Liu, G., Gao, X., Li, W., Lü, H., Zhan, P., Lv, T., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.72 · Cited by 46
Hirashima, T., Kanai, T., Suzuki, H., Yoshida, H., MATSUSHITA, A., KAWASUMI, H., Samejima, Y., Noda, Y., Nasu, S., Tanaka, A., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13832 · Cited by 44
Wang, W., Hao, Y., Liu, Y., Li, R., Huang, D., & Pan, Y. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1654 · Cited by 47
Makowska, A. M., Meier, S., Shen, L., Busson, P., Baloche, V. M. D., & Kontny, U. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02681-x · Cited by 44
Chen, X., Zhang, Z., Hou, X., Zhang, Y., Zhou, T., Liu, J., Lin, Z., Fang, W., Yang, Y., Ma, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001170 · Cited by 44
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Leighl, N. B., Laurie, S. A., Goss, G. D., Hughes, B. G. M., Stockler, M. R., Tsao, M., Hwang, D. M., Joubert, P., Kulkarni, S., Blais, N., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.023 · Cited by 47
Li, M., Hou, X., Sai, K., Wu, L., Chen, J., Zhang, B., Wang, N., Wu, L., Zheng, H., Zhang, J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2059874 · Cited by 49
Rusch, V. W., Nicholas, A., Patterson, G. A., Waqar, S. N., Toloza, E. M., Haura, E. B., Raz, D. J., Reckamp, K. L., Merritt, R. E., Owen, D. H., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.10.007 · Cited by 43
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 46
Current management of RET rearranged non-small cell lung cancer
Stinchcombe, T. E. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920928634 · Cited by 43
Huang, Q., Zheng, Y., Gao, Z., Yuan, L., Sun, Y., & Chen, H. (2020) · Journal of Cancer · doi:10.7150/jca.49325 · Cited by 44
Bilger, G., Girard, N., Doubre, H., Levra, M. G., Leprieur, E. G., Giraud, F., Decroisette, C., Carton, M., & Massiani, M. A. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03114-z · Cited by 44
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 47
Arasanz, H., Bocanegra, A., Morilla, I., Fernández‐Irigoyen, J., Martínez-Aguillo, M., Teijeira, L., Garnica, M., Blanco, E., Chocarro, L., Ausín, K., et al. (2022) · Cancers · doi:10.3390/cancers14163846 · Cited by 47
Gridelli, C., Peters, S., Mok, T. S. K., Forde, P. M., Reck, M., Attili, I., & de Marinis, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100355 · Cited by 41
Liquid Biopsies in Lung Cancer
Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A. B., & Bleckmann, A. (2023) · Cancers · doi:10.3390/cancers15051430 · Cited by 42
Xuzhang, W., Lü, T., Jin, W., Yu, Y., Li, Z., Shen, L., Niu, X., Ai, X., Xia, L., & Lü, S. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.89080 · Cited by 42
Parra, E. R., Zhang, J., Duose, D. Y., Gonzalez‐Kozlova, E., Redman, M. W., Chen, H., Manyam, G. C., Kumar, G., Zhang, J., Song, X., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0251 · Cited by 43
Matsumoto, Y., Sawa, K., Fukui, M., Oyanagi, J., Izumi, M., Ogawa, K., Suzumura, T., Watanabe, T., Kaneda, H., Mitsuoka, S., et al. (2019) · Cancer Science · doi:10.1111/cas.14156 · Cited by 43
Califano, R., Gomes, F., Ackermann, C. J., Rafee, S., Tsakonas, G., & Ekman, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.010 · Cited by 42
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
Shao, J., Wang, C., Ren, P., Jiang, Y., Tian, P., & Li, W. (2020) · Bioscience Reports · doi:10.1042/bsr20192347 · Cited by 46
Popat, S., Grohé, C., Corral, J., Reck, M., Novello, S., Gottfried, M., Radonjic, D., & Kaiser, R. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.009 · Cited by 42
Self-citationSurvival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
Bomze, D., Asher, N., Ali, O. H., Flatz, L., Azoulay, D., Markel, G., & Meirson, T. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.17675 · Cited by 42
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
Bebb, D. G., Banerji, S. O., Blais, N., Desmeules, P., Gill, S., Grin, A., Feilotter, H. E., Hansen, A. R., Hyrcza, M. D., Krzyzanowska, M. K., et al. (2021) · Current Oncology · doi:10.3390/curroncol28010053 · Cited by 42
Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy
Janowitz, T., Kleeman, S., & Vonderheide, R. H. (2021) · The Oncologist · doi:10.1002/onco.13680 · Cited by 42
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Maritaz, C., Broutin, S., Chaput, N., Marabelle, A., & Paci, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01182-3 · Cited by 45
Immune Checkpoint Inhibitors and Chemotherapy in First-Line NSCLC: a Meta-Analysis
Petrelli, F., Ferrara, R., Signorelli, D., Ghidini, A., Proto, C., Roudi, R., Sabet, M. N., Facelli, S., Garassino, M. C., Luciani, A., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0224 · Cited by 42
Szeto, C. H., Shalata, W., Yakobson, A., & Agbarya, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235614 · Cited by 41
Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer
Tanaka, K., Chamoto, K., Saeki, S., Hatae, R., Ikematsu, Y., Sakai, K., Ando, N., Sonomura, K., Kojima, S., Taketsuna, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0021 · Cited by 41
Zhou, X., Zhou, L., Yao, Z., Huang, M., Gong, Y., Zou, B., Zhu, J., Liu, Y., Peng, F., Zhang, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0315 · Cited by 43
Immunotherapy in extensive small cell lung cancer
Verma, V., Sharma, G., & Singh, A. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0129-x · Cited by 42
Wei, Y., Du, Q., Jiang, X., Li, L., Li, T., Li, M., Fan, X., Li, Y., Kariminia, S., & Li, Q. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.008 · Cited by 39
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 40
Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity
Inao, T., Kotani, H., Iida, Y., Kartika, I. D., Okimoto, T., Tanino, R., Shiba, E., & Harada, M. (2019) · Cancer Science · doi:10.1111/cas.14116 · Cited by 41
Ohba, T., Takamori, S., Toyozawa, R., Nosaki, K., Umeyama, Y., Haratake, N., Miura, N., Yamaguchi, M., Taguchi, K., Seto, T., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.09.29 · Cited by 42
Kagawa, Y., Furuta, H., Uemura, T., Watanabe, N., Shimizu, J., Horio, Y., Kuroda, H., Inaba, Y., Kodaira, T., Masago, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14605 · Cited by 42
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
Duchemann, B., Remón, J., Naigeon, M., Mezquita, L., Ferrara, R., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., et al. (2020) · Cancers · doi:10.3390/cancers12123625 · Cited by 42
Boilève, A., Hilmi, M., Gougis, P., Cohen, R., Rousseau, B., Blanc, J., Abdelghani, M. B., Castanié, H., Dahan, L., Tougeron, D., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.027 · Cited by 41
Man, J., Millican, J., Mulvey, A., Gebski, V., & Hui, R. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab012 · Cited by 40
Platinum-based chemotherapy via nanocarriers and co-delivery of multiple drugs
Xian, C., Chen, H., Xiong, F., Fang, Y., Huang, H. W., & Wu, J. (2021) · Biomaterials Science · doi:10.1039/d1bm00879j · Cited by 41
Tanaka, I., Furukawa, T., & Morise, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02165-7 · Cited by 42
Zhou, C., Li, M., Wang, Z., An, D., & Li, B. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108353 · Cited by 41
Li, H., Zhang, Y., Liang, L., Song, J., Wei, Z., Yang, S., Ma, Y., Chen, W. R., Lu, C., & Wen, L. (2022) · Materials · doi:10.3390/ma15031096 · Cited by 41
Tang, M., Abbas, H. A., Negrao, M. V., Ramineni, M., Hu, X., Hubert, S. M., Fujimoto, J., Reuben, A., Varghese, S., Zhang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27341-1 · Cited by 43
Ah, S., Yu, H.-Y., Choi, Y., Park, S., Sun, J., Lee, S., Ahn, J. S., Ahn, M., Choi, D.-H., Kim, K., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.2002 · Cited by 40
Chen, M., Ma, P., Zhang, Y., Wang, D., Yu, Z., Fu, Y., Zhao, X., Wang, M., Zhuang, G., & Jing, Y. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007305 · Cited by 43
Schöne, N., Kemper, M., Menck, K., Evers, G., Krekeler, C., Schulze, A. B., Lenz, G., Wardelmann, E., Binder, C. R., & Bleckmann, A. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12418 · Cited by 41
Wang, C., Kulkarni, P., & Salgia, R. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.02.001 · Cited by 40
de Jong, C., Deneer, V. H. M., Kelder, J. C., Ruven, H. J. T., Egberts, T. C. G., & Herder, G. J. M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13449 · Cited by 40
Gomes, F., Wong, M. L., Battisti, N. M. L., Kordbacheh, T., Kiderlen, M., Greystoke, A., & Luciani, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0986-4 · Cited by 41
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
Lurain, K. A., Ramaswami, R., Yarchoan, R., & Uldrick, T. S. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00525-y · Cited by 42
Immunotherapy in Advanced Biliary Tract Cancers
Boilève, A., Hilmi, M., Smolenschi, C., Ducreux, M. P., Hollebecque, A., & Malka, D. (2021) · Cancers · doi:10.3390/cancers13071569 · Cited by 41
Wu, F., Gu, Y., Kang, B., Heskia, F., Pachot, A., Bonneville, M., Wei, P., & Liang, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1277 · Cited by 42
Insa, A., Martín-Martorell, P., Liello, R. D., Fasano, M., Martini, G., Napolitano, S., Vicidomini, G., Cappabianca, S., Franco, R., Morgillo, F., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103538 · Cited by 42
Xu, H., Feng, H., Zhang, W., Wei, F., Zhou, L., Liu, L., Zhao, Y., Lv, Y., Shi, X., Zhang, J., et al. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113157 · Cited by 40
Federico, A. D., Giglio, A. D., Gelsomino, F., Sperandi, F., Melotti, B., & Ardizzoni, A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac205 · Cited by 40
Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.012 · Cited by 40
Self-citationShoji, F., Yamaguchi, M., Okamoto, M., Takamori, S., Yamazaki, K., Okamoto, T., & Maehara, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1040424 · Cited by 40
Barlési, F., Isambert, N., Felip, E., Cho, B. C., Lee, D. H., Peguero, J. A., Jérusalem, G., Penel, N., Saâda-Bouzid, E., Garrido, P., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac253 · Cited by 40
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Strati, A. D., Adamopoulos, C., Kotsantis, I., Psyrri, A. K., Lianidou, E. S., & Papavassiliou, A. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031235 · Cited by 41
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer
Melosky, B. L., Juergens, R. A., Hirsh, V., McLeod, D., Leighl, N. B., Tsao, M., Card, P. B., & Chu, Q. S.-C. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0027 · Cited by 40
Seto, T., Azuma, K., Yamanaka, T., Sugawara, S., Yoshioka, H., Wakuda, K., Atagi, S., Iwamoto, Y., Hayashi, H., Okamoto, I., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01494 · Cited by 38
Self-citationZhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 40
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
on behalf of the German Study Group of Bladder Cancer (DFBK e.V.), Morsch, R., Rose, M., Maurer, A., Cassataro, M. A., Braunschweig, T. A., Knüchel, R., Vögeli, T., Ecke, T., Eckstein, M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06727-2 · Cited by 39
Käsmann, L., Eze, C., Taugner, J., Roengvoraphoj, O., Dantes, M., Schmidt-Hegemann, N.-S., Schiopu, S., Belka, C., & Manapov, F. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01595-3 · Cited by 40
Li, X., Wang, L., Chen, S., Zhou, F., Zhao, J., Zhao, W., & Su, C. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13597 · Cited by 39
Self-citationCabezas-Camarero, S., Cabrera‐Martín, M. N., Merino‐Menéndez, S., Paz-Cabezas, M., García‐Barberán, V., Sanz, M. S., Iglesias-Moreno, M.-C., Alonso‐Oviés, A., & Pérez‐Segura, P. (2021) · The Oncologist · doi:10.1002/onco.13754 · Cited by 39
Thouvenin, L., Olivier, T., Banna, G. L., Addeo, A., & Friedlaender, A. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986211004745 · Cited by 43
Facchinetti, F., Maïo, M. D., Perrone, F., & Tiseo, M. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-15 · Cited by 39
Akhbariyoon, H., Azizpour, Y., Esfahani, M. F., Firoozabad, M. S. M., Rad, M. R., Esfahani, K. S., Khoshavi, N., Karimi, N., Shirinisaz, A., Abedi, F., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108873 · Cited by 40
International consensus on radiotherapy in metastatic non-small cell lung cancer
Zhu, Z., Ni, J., Cai, X., Su, S., Zhuang, H., Yang, Z., Chen, M., Ma, S., Xie, C., Xu, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-644 · Cited by 39
Wu, J., Hou, L., Haoran, E., Zhao, Y., Yu, X., Xu, L., Ye, N., Deng, J., Sun, K., Zhang, J., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.019 · Cited by 39
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
Pabst, L., Lopes, S., Bertrand, B., Creusot, Q., Kotovskaya, M., Pencreach, E., Beau‐Faller, M., & Mascaux, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087577 · Cited by 37
Cao, L., Wang, J., Zhang, Y., Rong, Z., Wang, M., Wang, L., Ji, J., Qian, Y., Zhang, L., Wu, H., et al. (2023) · Medical Image Analysis · doi:10.1016/j.media.2023.102837 · Cited by 42
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 39
Metadata
- Authors
- Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., & Kowalski, D. M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) — both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) — both in Turkey; Centre...
- Ankara University (TR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 2040-2051
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2892640821
- Cited by
- 3,617
- References
- 26
- Citations by year
- 2026: 220 · 2025: 328 · 2024: 445 · 2023: 440 · 2022: 565 · 2021: 630 · 2020: 606 · 2019: 361 · 2018: 16
- FWCI
- 303.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Merck (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, lung squamous cell carcinoma, metastatic lung cancer, PD-L1 expression, immune checkpoint inhibitors, carboplatin, paclitaxel, nab-paclitaxel, first-line therapy, overall survival, progression-free survival, immune-related adverse events, treatment discontinuation, chemoimmunotherapy, PD-1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Carboplatin, Paclitaxel, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
